MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

13 Jan 2025 06:45:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

03 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

07 Nov 2024 11:24:15 By NetDania Notify

NetDania - New 12 months High: MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

06 Nov 2024 09:45:20 By NetDania Notify

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

06 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

05 Nov 2024 16:15:01 By NetDania Notify

NetDania - New 12 months High: MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

04 Nov 2024 09:47:38 By NetDania Notify

NetDania - New 12 months High: MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

01 Nov 2024 10:37:32 By NetDania Notify

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

31 Oct 2024 07:00:01 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

30 Oct 2024 08:00:22 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

21 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

18 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

02 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

01 Oct 2024 08:00:01 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)

30 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

26 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates

07 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

02 Aug 2024 07:00:21 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024

24 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress

06 Jun 2024 08:00:00 By Nasdaq GlobeNewswire